HLA-DRB1 Antibody

What is HLA-DRB1 and what role does it play in immune function?

HLA-DRB1 is a component of the Major Histocompatibility Complex (MHC) class II molecules, specifically encoding the beta chain of the DR receptor. This protein plays a critical role in antigen presentation to CD4+ T cells, forming a peptide-binding groove that determines which antigens can be presented. The molecular weight of HLA-DRB1 is calculated at approximately 30 kDa (266 amino acids), though observed experimental molecular weight typically ranges between 27-30 kDa .

The gene is highly polymorphic, with specific allelic variations strongly associated with various autoimmune conditions, particularly rheumatoid arthritis (RA). Research indicates that amino acid positions 11, 71, and 74 are particularly important in determining disease association and treatment response profiles .

What are the primary applications for HLA-DRB1 antibodies in research settings?

HLA-DRB1 antibodies serve as valuable tools across multiple research applications. According to experimental validation, these antibodies demonstrate effectiveness in:

• Western Blot (WB): Successfully detecting HLA-DRB1 protein in Raji cells, human spleen tissue, A375 cells, and Daudi cells

• Immunoprecipitation (IP): Validated for use with Raji cells

• Immunohistochemistry (IHC): Validated in human tonsillitis tissue

• Immunofluorescence/Immunocytochemistry (IF/ICC): Successfully visualizing HLA-DRB1 in Raji cells

These applications enable researchers to investigate HLA-DRB1 expression patterns, protein-protein interactions, tissue localization, and functional characteristics across diverse experimental contexts.

What are the recommended protocols and dilutions for HLA-DRB1 antibody applications?

For IHC applications specifically, research protocols suggest using 5 μg/ml concentration with a 1-hour room temperature incubation period. Importantly, heat-induced epitope retrieval is typically necessary before antibody application, with optimized results using either TE buffer (pH 9.0) or citrate buffer (pH 6.0) .

What sample preparation techniques enhance HLA-DRB1 detection sensitivity?

Effective sample preparation is crucial for reliable HLA-DRB1 detection. For paraffin-embedded tissue sections, heat-induced epitope retrieval significantly improves antibody accessibility. The recommended approach includes:

• Deparaffinize and rehydrate tissue sections using standard protocols

• Perform heat-induced epitope retrieval using VisUCyte Antigen Retrieval Reagent-Basic or equivalent

• Apply primary antibody at appropriate dilution (typically 5 μg/ml for IHC applications)

• Detect using compatible secondary detection systems such as HRP-polymer antibodies

• Visualize with DAB (3,3'-diaminobenzidine) chromogen and counterstain with hematoxylin

This approach results in specific cell surface staining pattern characteristic of HLA-DRB1 expression. For Western blotting applications, optimized protocols are available from antibody manufacturers and should be followed for consistent results .

How are specific HLA-DRB1 alleles associated with rheumatoid arthritis susceptibility?

Numerous studies have identified significant associations between specific HLA-DRB1 alleles and rheumatoid arthritis risk. Research in diverse populations demonstrates:

• HLA-DRB104 and HLA-DRB110 alleles occur at significantly higher frequencies in RA patients compared to controls (9.6% vs 5.1%, P = 0.038 and 14.2% vs 8.2%, P = 0.042, respectively)

• These risk alleles show particular association with anti-citrullinated protein antibodies (ACPA) seropositivity

• Conversely, HLA-DRB1*07 appears protective, with significantly lower frequency in RA patients (5.0%) compared to controls (11.7%, P = 0.010)

These associations suggest distinct genetic contributions to disease pathogenesis, potentially reflecting different immunological mechanisms in RA development and progression.

How do HLA-DRB1-DQB1 haplotypes influence rheumatoid arthritis risk?

Analysis of HLA haplotypes provides more comprehensive insight into genetic risk factors than individual alleles alone. Research has identified specific HLA-DRB1-DQB1 haplotypes that confer either increased risk or protection against RA:

These haplotype associations suggest complex genetic interactions determining RA susceptibility, with potential implications for personalized risk assessment and treatment strategies .

Can HLA-DRB1 genotyping predict treatment response in rheumatoid arthritis patients?

Emerging research indicates potential for HLA-DRB1 as a predictive biomarker for treatment response. Recent findings demonstrate:

• Val11 of HLA-DRB1 may predict favorable treatment response to abatacept in seropositive RA patients

• Significant association exists between good response to abatacept and shared epitope (SE) with Val11 (P = 5.4 × 10-3)

• The VRA haplotype (Val at position 11, Arg at position 71, and Ala at position 74) of HLA-DRB1 correlates with improved treatment outcomes (P = 0.013)

• These associations appear specific to abatacept therapy and were not observed with TNF inhibitor treatment

These findings suggest potential clinical utility of HLA-DRB1 genotyping for guiding personalized therapeutic selections, potentially improving treatment outcomes by matching patients with optimal biological disease-modifying antirheumatic drugs (bDMARDs).

How do HLA-DRB1 polymorphisms at specific amino acid positions affect protein function?

Detailed structural and functional analyses indicate that polymorphisms at specific amino acid positions within HLA-DRB1 significantly impact protein function and disease associations:

• Positions 11, 71, and 74 appear particularly critical for determining RA risk

• These positions influence the peptide-binding groove structure, thereby affecting antigen presentation capacity

• The VRA haplotype (Val11, Arg71, Ala74) demonstrates association with treatment response patterns

• Molecular modeling suggests these positions affect both peptide binding affinity and T-cell receptor recognition

Understanding these structure-function relationships provides mechanistic insight into how genetic variations translate to immunological differences and ultimately disease predisposition or protection.

How does the interaction between HLA-DRB1 genotypes and serological markers impact RA disease phenotype?

The relationship between HLA-DRB1 genotypes and serological markers reveals distinct disease subgroups with potential clinical implications:

• HLA-DRB1*04 and *10 alleles show strong association with ACPA positivity (22.2% vs 8.8%, P = 0.044 and 23.8% vs 8.8%, P = 0.027, respectively)

• HLA-DRB1*08 frequency is significantly higher in ACPA-negative patients compared to ACPA-positive individuals (24.6% vs 4.8%, P = 0.002)

• No significant associations were observed between RF (rheumatoid factor) antibody status and HLA-DRB1 alleles

• These findings suggest ACPA, rather than RF, plays a more direct role in RA pathogenesis related to HLA genotypes

These observations support the concept of RA as a heterogeneous disease with genetically distinct subgroups that may benefit from different therapeutic approaches.

What experimental considerations are important when studying rare HLA-DRB1 alleles?

Investigating rare HLA-DRB1 alleles presents unique challenges requiring specialized approaches:

• Population selection: Certain alleles show significant frequency variations across ethnic groups; therefore, study populations should be carefully selected and stratified

• Sample size determination: Power calculations should account for allele frequency in the target population to ensure sufficient representation of rare variants

• Genotyping methodology: High-resolution techniques such as next-generation sequencing are preferred over traditional PCR-SSP methods for rare allele detection

• Statistical analysis: Standard statistical approaches may require modification when analyzing rare variants; specialized methods like collapsing rare variant tests should be considered

• Functional validation: In vitro peptide binding assays and T-cell stimulation experiments may provide critical insights into functional consequences of rare allelic variants

These considerations help ensure robust and reproducible findings when investigating less common HLA-DRB1 alleles that may still carry significant clinical implications for subgroups of patients.